Protocol · Cancer Support
Liver Cancer (Hepatocellular Carcinoma) Supportive Care Protocol
Vitamin D and Omega-3 Fatty Acids are the core of this stack, with 6 supporting supplements. Each row gives the amount the protocol lists and the grade our evidence database holds for that supplement in Liver Cancer (Hepatocellular Carcinoma) Supportive Care.
We are re-verifying the studies cited on protocol pages; only confirmed citations are shown.
The stack
8 supplements · 1 graded
| Grade | Supplement | Amount listed | Why it’s in the stack | Evidence on file |
|---|---|---|---|---|
| Primary stackThe core of this protocol | ||||
| Vitamin D | Amount listed: 2,000–4,000 IU daily (may need higher doses in cirrhosis; monitor levels) | Deficiency common in liver disease and associated with worse HCC outcomes; supports immune function | Not graded yet | |
| Omega-3 Fatty Acids | Amount listed: 2–3 g EPA+DHA daily | Anti-inflammatory effects; may help with cancer-related cachexia and support liver function | Not graded yet | |
| Supporting stackListed as additions to the core | ||||
| Vitamin K | Amount listed: 45 mg vitamin K2 (MK-4) daily (in studies); lower for general support | May have antiproliferative effects in HCC; deficiency common in liver disease
| Grade B for Cancer Mortality1,980 people | |
| Milk Thistle (Silymarin) | Amount listed: 420–600 mg silymarin daily in divided doses | Hepatoprotective effects; antioxidant; may reduce treatment side effects | Not graded yet | |
| Curcumin | Amount listed: 500–1,000 mg enhanced-absorption curcumin daily | Anti-cancer properties in preclinical studies; may inhibit HCC proliferation | Not graded yet | |
| Branched-Chain Amino Acids (BCAAs) | Amount listed: 5–12 g BCAAs daily | Support liver function; reduce muscle loss in cirrhosis; may improve outcomes after treatment | Not graded yet | |
| Zinc | Amount listed: 25–50 mg daily (monitor copper with long-term use) | Deficiency common in liver disease; supports immune function and liver metabolism | Not graded yet | |
| Selenium | Amount listed: 100–200 mcg daily (avoid excess) | Antioxidant; deficiency associated with increased liver cancer risk in endemic areas | Not graded yet | |
How this protocol works
In plain language
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, usually arising in the setting of chronic liver disease. Major risk factors include hepatitis B or C infection, cirrhosis from any cause (alcohol, fatty liver disease), aflatoxin exposure, and certain metabolic conditions. HCC is often diagnosed late because the diseased liver may not show symptoms until cancer is advanced. Treatment depends on stage and liver function and may include surgery, transplant, ablation, chemoembolization, or systemic therapy.
CRITICAL: Liver cancer requires comprehensive oncological management. Treatment decisions depend on tumor stage, liver function (Child-Pugh score), and performance status. Options include surgical resection, liver transplantation (for appropriate candidates), ablation, transarterial chemoembolization (TACE), radioembolization, or systemic therapies (sorafenib, lenvatinib, immunotherapy). These supplements may provide supportive benefit but DO NOT treat cancer. Always discuss supplements with your oncology team as some may interact with treatments. Addressing underlying liver disease (viral hepatitis, alcohol) is crucial.
Vitamin D* deficiency is very common in liver disease (the liver converts vitamin D to its active form). Low vitamin D levels are associated with worse HCC outcomes. Supplementation supports immune function and may be beneficial.
Omega-3 Fatty Acids* have anti-inflammatory effects and may help with cancer-related weight loss (cachexia). They also support liver function.
Vitamin K* has shown potential antiproliferative effects against HCC in some studies, particularly vitamin K2 (menatetrenone). Deficiency is common in liver disease due to impaired absorption and storage.
Milk Thistle (Silymarin)* has hepatoprotective and antioxidant properties. It may help protect remaining liver function and reduce treatment side effects.
Curcumin* has shown anti-cancer effects against HCC in laboratory studies, including inhibiting cell proliferation and inducing apoptosis.
Branched-Chain Amino Acids (BCAAs)* are often depleted in cirrhosis. Supplementation can help maintain muscle mass, improve nutritional status, and may improve outcomes after HCC treatment.
Zinc* deficiency is very common in chronic liver disease and contributes to complications. Supplementation supports liver function and immune health.
Selenium* deficiency has been associated with increased liver cancer risk, particularly in areas with endemic low selenium levels.
Expected timeline: Nutritional support is ongoing throughout treatment. Discuss any supplements with your oncologist before starting.